Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Plos One|January 5, 2011
Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokinesEric Tran, Julie S Nielsen, Darin A Wick, et al.
Human Reproduction (Oxford, England)|January 27, 2010
Preclinical validation of a microarray method for full molecular karyotyping of blastomeres in a 24-h protocolD S Johnson, G Gemelos, J Baner, et al.
Annals of Internal Medicine|October 15, 1993
Reliability of histologic scoring for lupus nephritis: a community-based evaluationR M Wernick, D L Smith, D C Houghton, et al.
Marine Environmental Research|February 20, 2020
Macroinfauna responses and recovery trajectories after an oil spill differ from those following saltmarsh restorationJ W Fleeger, D S Johnson, S Zengel, et al.
NPJ Precision Oncology|July 19, 2023
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibitionHussein Al-Sudani, Ying Ni, Philip Jones, et al.
Journal of Medical Genetics|October 15, 2016
Chitayat syndrome: hyperphalangism, characteristic facies, hallux valgus and bronchomalacia results from a recurrent c.266A>G p.(Tyr89Cys) variant in the ERF geneM Balasubramanian, H Lord, S Levesque, et al.
Frontiers in Immunology|March 13, 2025
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacyMithunah Krishnamoorthy, Ruth Seelige, Christopher R Brown, et al.
Blood Advances|April 10, 2019
Targeting CD47 in Sézary syndrome with SIRPαFcLisa D S Johnson, Swati Banerjee, Oleg Kruglov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2026
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE StudyDavid A Sallman, Guillermo Garcia-Manero, Naval Daver, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic MalignanciesStephen M Ansell, Michael B Maris, Alexander M Lesokhin, et al.
Pageof 8